Structured Review

Abcam antibody against cdcp1
Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including <t>CDCP1.</t> (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.
Antibody Against Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against cdcp1/product/Abcam
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
antibody against cdcp1 - by Bioz Stars, 2023-09
86/100 stars

Images

1) Product Images from "Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer"

Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

Journal: Frontiers in Oncology

doi: 10.3389/fonc.2023.1142755

Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including CDCP1. (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.
Figure Legend Snippet: Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including CDCP1. (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.

Techniques Used: Derivative Assay, Electron Microscopy, Expressing

The CDCP1 + EVs cluster was enriched in the ascites of OVCA patients. (A) All samples were divided into twenty-eight clusters and demonstrated in the tSNE plot. (B) The Percentile of each subgroup and its characteristic protein. (C) EVs in ovarian cancer ascites and benign ascites. (D) tSNE of each sample with ovarian cancer and the control group. (E) OVCA ascites are mainly concentrated in cluster 4. (F) Major protein constituent of cluster 4.
Figure Legend Snippet: The CDCP1 + EVs cluster was enriched in the ascites of OVCA patients. (A) All samples were divided into twenty-eight clusters and demonstrated in the tSNE plot. (B) The Percentile of each subgroup and its characteristic protein. (C) EVs in ovarian cancer ascites and benign ascites. (D) tSNE of each sample with ovarian cancer and the control group. (E) OVCA ascites are mainly concentrated in cluster 4. (F) Major protein constituent of cluster 4.

Techniques Used:

CDCP1 expression is associated with the prognosis of ovarian cancer patients. (A) CDCP1 expression level was positively linked with ovarian cancer in TCGA. (B) CDCP1 levels in the ascites were assessed using sandwich enzyme-linked immunosorbent assay (p < 0.05). (C) CDCP1 levels in the serum were assessed by the sandwich ELISA (p < 0.0001). (D) CDCP1 low and high expression as determined by IHC staining, scale bar 50 µm. (E) CDCP1 express level influenced survival. (F) Overall, greater ki-67 expression was associated with a shorter survival duration than low expression. (G, H) Overall and disease-free survival times of the group with high CDCP1 expression were significantly shorter than those with low CDCP1 expression. *p < 0.05, **p < 0.01, ****p < 0.0001.
Figure Legend Snippet: CDCP1 expression is associated with the prognosis of ovarian cancer patients. (A) CDCP1 expression level was positively linked with ovarian cancer in TCGA. (B) CDCP1 levels in the ascites were assessed using sandwich enzyme-linked immunosorbent assay (p < 0.05). (C) CDCP1 levels in the serum were assessed by the sandwich ELISA (p < 0.0001). (D) CDCP1 low and high expression as determined by IHC staining, scale bar 50 µm. (E) CDCP1 express level influenced survival. (F) Overall, greater ki-67 expression was associated with a shorter survival duration than low expression. (G, H) Overall and disease-free survival times of the group with high CDCP1 expression were significantly shorter than those with low CDCP1 expression. *p < 0.05, **p < 0.01, ****p < 0.0001.

Techniques Used: Expressing, Sandwich ELISA, Immunohistochemistry

The  CDCP1  expression level varied between different stages.
Figure Legend Snippet: The CDCP1 expression level varied between different stages.

Techniques Used: Expressing

The diagnostic value of single EV protein biomarkers. (A) Multiple protein combinations are created in the OVCA group. (B) Characteristic protein combination constituted of CDCP1 in the OVCA group. (C) The receiver operating characteristic (ROC) curve for CDCP1. (D) The ROC curve for the combination of proteins CDCP1 and ITGA6.
Figure Legend Snippet: The diagnostic value of single EV protein biomarkers. (A) Multiple protein combinations are created in the OVCA group. (B) Characteristic protein combination constituted of CDCP1 in the OVCA group. (C) The receiver operating characteristic (ROC) curve for CDCP1. (D) The ROC curve for the combination of proteins CDCP1 and ITGA6.

Techniques Used: Diagnostic Assay


Structured Review

Abcam cdcp1
8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for <t>CDCP1</t> reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.
Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdcp1/product/Abcam
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cdcp1 - by Bioz Stars, 2023-09
86/100 stars

Images

1) Product Images from "Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment"

Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

Journal: Molecular Oncology

doi: 10.1002/1878-0261.13429

8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for CDCP1 reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.
Figure Legend Snippet: 8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for CDCP1 reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.

Techniques Used: Library Screening, Western Blot, Migration, Standard Deviation

8‐Isopentenylnaringenin dose‐dependently suppresses lung cancer colony formation and sphere formation ability. (A) Colony formation was analyzed after 7 days of 8PN treatment in TC1, Bm7, and H1650 cells. Experiments were performed in three replicate wells. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (B) The number of spheres was measured 12 days post‐treatment in TC1 cells with 20 μ m 8PN, Bm7 cells with 25 μ m 8PN, and H1650 cells with 12.5 μ m 8PN ( n = 3). Scale bar, 50 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (C) Immunoblotting analysis of CDCP1, CD44, and CD133 in Bm7 sphere cells with 25 μ m 8PN and H1650 sphere cells with 50 μ m 8PN for 9 days. Actin was the loading control. Experiments were repeated in three times.
Figure Legend Snippet: 8‐Isopentenylnaringenin dose‐dependently suppresses lung cancer colony formation and sphere formation ability. (A) Colony formation was analyzed after 7 days of 8PN treatment in TC1, Bm7, and H1650 cells. Experiments were performed in three replicate wells. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (B) The number of spheres was measured 12 days post‐treatment in TC1 cells with 20 μ m 8PN, Bm7 cells with 25 μ m 8PN, and H1650 cells with 12.5 μ m 8PN ( n = 3). Scale bar, 50 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (C) Immunoblotting analysis of CDCP1, CD44, and CD133 in Bm7 sphere cells with 25 μ m 8PN and H1650 sphere cells with 50 μ m 8PN for 9 days. Actin was the loading control. Experiments were repeated in three times.

Techniques Used: Standard Deviation, Western Blot

8‐Isopentenylnaringenin induces cell cycle arrest in G0/G1 phase and senescence. (A) Immunoblotting analysis of cell cycle proteins in Bm7 cells with 25 μ m 8PN and H1650 cells with 50 μ m 8PN for 48 h. Actin was the loading control. (B) β‐Galactosidase staining in lung cancer cells after treatment with the indicated dose of 8PN for 6 days. The number of senescent cells was quantified using the imagej software. Representative images shown in the lower panel. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. (C) β‐Galactosidase staining in CDCP1‐depleted lung cancer cells after treatment with the indicated dose of 8PN for 6 days. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05, ** P < 0.01.
Figure Legend Snippet: 8‐Isopentenylnaringenin induces cell cycle arrest in G0/G1 phase and senescence. (A) Immunoblotting analysis of cell cycle proteins in Bm7 cells with 25 μ m 8PN and H1650 cells with 50 μ m 8PN for 48 h. Actin was the loading control. (B) β‐Galactosidase staining in lung cancer cells after treatment with the indicated dose of 8PN for 6 days. The number of senescent cells was quantified using the imagej software. Representative images shown in the lower panel. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. (C) β‐Galactosidase staining in CDCP1‐depleted lung cancer cells after treatment with the indicated dose of 8PN for 6 days. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05, ** P < 0.01.

Techniques Used: Western Blot, Staining, Software, Standard Deviation

Loss of CDCP1 in lung cancer cells significantly increases lung cancer cell death. (A) Levels of CDCP1, caspase 3, phospho‐EGFR, and phospho‐ERK were detected in H1650 cells treated with 50 μ m 8PN and/or 2.5 μ m afatinib (left) and H1975 cells treated with 40 μ m 8PN and/or 1 μ m AZD (right). Experiments were repeated in three times. (B) Levels of indicated proteins were detected in control (shVOID) and CDCP1 knockdown (shCDCP1) H1650 (left) and H1975 (right) cells treated with 1 μ m afatinib or 10 μ m AZD. Experiments were repeated in three times. (C) H1650 ( n = 6) and H1975 cells ( n = 4) were treated with EGFR TKI for 3 and 9 days, respectively. The cell viability was assessed by colony formation assays. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. ** P < 0.01.
Figure Legend Snippet: Loss of CDCP1 in lung cancer cells significantly increases lung cancer cell death. (A) Levels of CDCP1, caspase 3, phospho‐EGFR, and phospho‐ERK were detected in H1650 cells treated with 50 μ m 8PN and/or 2.5 μ m afatinib (left) and H1975 cells treated with 40 μ m 8PN and/or 1 μ m AZD (right). Experiments were repeated in three times. (B) Levels of indicated proteins were detected in control (shVOID) and CDCP1 knockdown (shCDCP1) H1650 (left) and H1975 (right) cells treated with 1 μ m afatinib or 10 μ m AZD. Experiments were repeated in three times. (C) H1650 ( n = 6) and H1975 cells ( n = 4) were treated with EGFR TKI for 3 and 9 days, respectively. The cell viability was assessed by colony formation assays. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. ** P < 0.01.

Techniques Used: Standard Deviation

Schematic diagram showing that 8PN reduces CDCP1 protein levels and increases IL6 and IL8 expression in lung tumors to attract neutrophil infiltration. The combination of 8PN and EGFR TKI produces synergistic effects in lung cancer treatment.
Figure Legend Snippet: Schematic diagram showing that 8PN reduces CDCP1 protein levels and increases IL6 and IL8 expression in lung tumors to attract neutrophil infiltration. The combination of 8PN and EGFR TKI produces synergistic effects in lung cancer treatment.

Techniques Used: Expressing


Structured Review

Abcam cdcp1
Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdcp1/product/Abcam
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cdcp1 - by Bioz Stars, 2023-09
86/100 stars

Images


Structured Review

Abcam cdcp1 antibody
The level of <t>CDCP1</t> mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
Cdcp1 Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdcp1 antibody/product/Abcam
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
cdcp1 antibody - by Bioz Stars, 2023-09
86/100 stars

Images

1) Product Images from "Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging"

Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

Journal: iScience

doi: 10.1016/j.isci.2023.106103

The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
Figure Legend Snippet: The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

Techniques Used: Expressing

CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Cell Culture, Two Tailed Test

The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Expressing, Western Blot, Two Tailed Test

The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Two Tailed Test

Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).
Figure Legend Snippet: Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

Techniques Used: Imaging, Microscopy, Staining

The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.
Figure Legend Snippet: The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

Techniques Used: Two Tailed Test

The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Two Tailed Test


Figure Legend Snippet:

Techniques Used: Recombinant, Lysis, Blocking Assay, Western Blot, Software


Structured Review

Abcam rabbit monoclonal anti cdcp1
The level of <t>CDCP1</t> mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
Rabbit Monoclonal Anti Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal anti cdcp1/product/Abcam
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
rabbit monoclonal anti cdcp1 - by Bioz Stars, 2023-09
86/100 stars

Images

1) Product Images from "Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging"

Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

Journal: iScience

doi: 10.1016/j.isci.2023.106103

The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
Figure Legend Snippet: The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

Techniques Used: Expressing

CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Cell Culture, Two Tailed Test

The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Expressing, Western Blot, Two Tailed Test

The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Two Tailed Test

Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).
Figure Legend Snippet: Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

Techniques Used: Imaging, Microscopy, Staining

The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.
Figure Legend Snippet: The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

Techniques Used: Two Tailed Test

The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.
Figure Legend Snippet: The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

Techniques Used: Two Tailed Test


Figure Legend Snippet:

Techniques Used: Recombinant, Lysis, Blocking Assay, Western Blot, Software

antibodies rabbit monoclonal anti cdcp1 abcam cat  (Abcam)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Abcam antibodies rabbit monoclonal anti cdcp1 abcam cat
    Antibodies Rabbit Monoclonal Anti Cdcp1 Abcam Cat, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies rabbit monoclonal anti cdcp1 abcam cat/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies rabbit monoclonal anti cdcp1 abcam cat - by Bioz Stars, 2023-09
    86/100 stars

    Images


    Structured Review

    Abcam cdcp1 antibody
    Cdcp1 Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 antibody/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 antibody - by Bioz Stars, 2023-09
    86/100 stars

    Images


    Structured Review

    Abcam antibodies against cdcp1
    The expression of <t>CDCP1</t> in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade
    Antibodies Against Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against cdcp1 - by Bioz Stars, 2023-09
    86/100 stars

    Images

    1) Product Images from "Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma"

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    Journal: Cancer Cell International

    doi: 10.1186/s12935-021-02373-1

    The expression of CDCP1 in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade
    Figure Legend Snippet: The expression of CDCP1 in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade

    Techniques Used: Expressing

    The expression of CDCP1 was verified in glioma specimens from a southern hospital. Immunohistochemistry A verified CDCP1 expression in 35 samples of WHO grade II, 42 samples of WHO grade III and 55 samples of WHO grade IV glioma, and analysis of the immune scores B demonstrated that CDCP1 expression increased significantly with increasing WHO grade. Western blot C confirmed that CDCP1 expression was significantly increased in GBM (in the HCT116 human colorectal cancer cell line with high CDCP1 expression)
    Figure Legend Snippet: The expression of CDCP1 was verified in glioma specimens from a southern hospital. Immunohistochemistry A verified CDCP1 expression in 35 samples of WHO grade II, 42 samples of WHO grade III and 55 samples of WHO grade IV glioma, and analysis of the immune scores B demonstrated that CDCP1 expression increased significantly with increasing WHO grade. Western blot C confirmed that CDCP1 expression was significantly increased in GBM (in the HCT116 human colorectal cancer cell line with high CDCP1 expression)

    Techniques Used: Expressing, Immunohistochemistry, Western Blot

    Kaplan–Meier survival curve and multivariate Cox regression analyses of the CDCP1 risk score in the TCGA A – C (n = 667) and CGGA (B-D) datasets(n = 966)
    Figure Legend Snippet: Kaplan–Meier survival curve and multivariate Cox regression analyses of the CDCP1 risk score in the TCGA A – C (n = 667) and CGGA (B-D) datasets(n = 966)

    Techniques Used:

    Functional analysis of CDCP1 in GBM. GSEA (A-B) of GO functions and KEGG pathways of CDCP1 in the CGGA data. Identification of differentially expressed genes related to changes in CDCP1 expression ( C – D ). GO functional analysis E and KEGG pathway analysis F of 2408 upregulated genes
    Figure Legend Snippet: Functional analysis of CDCP1 in GBM. GSEA (A-B) of GO functions and KEGG pathways of CDCP1 in the CGGA data. Identification of differentially expressed genes related to changes in CDCP1 expression ( C – D ). GO functional analysis E and KEGG pathway analysis F of 2408 upregulated genes

    Techniques Used: Functional Assay, Expressing

    Verification of CDCP1 function in vitro. Transwell assays A and cell migration assays B showed that CDCP1 overexpression promoted the migration ability of glioma cells in vitro ( Wilcoxon rank-sum test)(the magnification is 200 times). Western blotting C was performed to detect the expression of N-cadherin, vimentin and Slug in the LV-CDCP1 and LV-Con groups
    Figure Legend Snippet: Verification of CDCP1 function in vitro. Transwell assays A and cell migration assays B showed that CDCP1 overexpression promoted the migration ability of glioma cells in vitro ( Wilcoxon rank-sum test)(the magnification is 200 times). Western blotting C was performed to detect the expression of N-cadherin, vimentin and Slug in the LV-CDCP1 and LV-Con groups

    Techniques Used: In Vitro, Migration, Over Expression, Western Blot, Expressing

    Analysis of the molecular mechanism of CDCP1 in GBM. Identification of key genes in the PPI network (A-B). High expression of CDCP1 was associated with MES-GBM. The correlation between CDCP1 expression and the mesenchymal C – E or proneural C – H signature was assessed using the CGGA database. Immunohistochemistry verification of the correlation between CDCP1 and CD44 expression ( I ). Western blot verification of the correlation between CDCP1 and CD44 expression J (Wilcoxon rank-sum test)
    Figure Legend Snippet: Analysis of the molecular mechanism of CDCP1 in GBM. Identification of key genes in the PPI network (A-B). High expression of CDCP1 was associated with MES-GBM. The correlation between CDCP1 expression and the mesenchymal C – E or proneural C – H signature was assessed using the CGGA database. Immunohistochemistry verification of the correlation between CDCP1 and CD44 expression ( I ). Western blot verification of the correlation between CDCP1 and CD44 expression J (Wilcoxon rank-sum test)

    Techniques Used: Expressing, Immunohistochemistry, Western Blot

    Correlation between the protein expression of  CDCP1  and CD44 in GBM tissue samples
    Figure Legend Snippet: Correlation between the protein expression of CDCP1 and CD44 in GBM tissue samples

    Techniques Used: Expressing

    Correlation between the protein expression of  CDCP1  and ITGAM in GBM tissue samples
    Figure Legend Snippet: Correlation between the protein expression of CDCP1 and ITGAM in GBM tissue samples

    Techniques Used: Expressing

    Establishment and verification of the prognostic risk model. Construction of a PPI network with key genes and CDCP1 ( A ). Establishment of the prognostic risk model comprising CDCP1, CD44 and ITGAM expression ( B ). Survival curves for glioma C and GBM D patients based on the prognostic risk model. Nomogram based on the risk model and clinicopathological factors. E: Glioma patient data. F: GBM patient data
    Figure Legend Snippet: Establishment and verification of the prognostic risk model. Construction of a PPI network with key genes and CDCP1 ( A ). Establishment of the prognostic risk model comprising CDCP1, CD44 and ITGAM expression ( B ). Survival curves for glioma C and GBM D patients based on the prognostic risk model. Nomogram based on the risk model and clinicopathological factors. E: Glioma patient data. F: GBM patient data

    Techniques Used: Expressing


    Structured Review

    Abcam rabbit anti cdcp1
    METTL3 modifies <t>CDCP1</t> through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.
    Rabbit Anti Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cdcp1 - by Bioz Stars, 2023-09
    86/100 stars

    Images

    1) Product Images from "Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer"

    Article Title: Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer

    Journal: Aging (Albany NY)

    doi: 10.18632/aging.103822

    METTL3 modifies CDCP1 through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.
    Figure Legend Snippet: METTL3 modifies CDCP1 through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.

    Techniques Used: Expressing, Western Blot, Quantitative RT-PCR, Luciferase, Activity Assay, CCK-8 Assay, Over Expression, Colony Assay, Transwell Assay, Standard Deviation

    EED accelerates the progression of GC in vivo through the miR-338-5p/METTL3/CDCP1 axis. ( A ) RT-qPCR to examine the expression of EED/miR-338-5p/METTL3/CDCP1 in tumors of nude mice, with β-actin and U6 as internal control, respectively. ( B ) Immunohistochemistry to detect METTL3 and CDCP1 expression in mouse tumors. ( C ) Tumor volume and tumor photos in response to EED knockdown and CDCP1 overexpression. ( D ) Quantitative analysis for tumor weight in response to EED knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. n = 6.
    Figure Legend Snippet: EED accelerates the progression of GC in vivo through the miR-338-5p/METTL3/CDCP1 axis. ( A ) RT-qPCR to examine the expression of EED/miR-338-5p/METTL3/CDCP1 in tumors of nude mice, with β-actin and U6 as internal control, respectively. ( B ) Immunohistochemistry to detect METTL3 and CDCP1 expression in mouse tumors. ( C ) Tumor volume and tumor photos in response to EED knockdown and CDCP1 overexpression. ( D ) Quantitative analysis for tumor weight in response to EED knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. n = 6.

    Techniques Used: In Vivo, Quantitative RT-PCR, Expressing, Immunohistochemistry, Over Expression, Standard Deviation

    The mechanism graph of the regulatory network and function of EED-mediated miR-338-5p methylation. EED methylates miR-338-5p to repress its expression, and upregulates expression of miR-338-5p’s target METTL3. METTL3 modifies CDCP1 mRNA through m6A to promote CDCP1 translation, leading to GC progression.
    Figure Legend Snippet: The mechanism graph of the regulatory network and function of EED-mediated miR-338-5p methylation. EED methylates miR-338-5p to repress its expression, and upregulates expression of miR-338-5p’s target METTL3. METTL3 modifies CDCP1 mRNA through m6A to promote CDCP1 translation, leading to GC progression.

    Techniques Used: Methylation, Expressing

    Primer sequences for RT-qPCR.
    Figure Legend Snippet: Primer sequences for RT-qPCR.

    Techniques Used: Sequencing


    Structured Review

    Abcam cdcp1
    Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 - by Bioz Stars, 2023-09
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Abcam antibody against cdcp1
    Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including <t>CDCP1.</t> (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.
    Antibody Against Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody against cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibody against cdcp1 - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    cdcp1  (Abcam)
    86
    Abcam cdcp1
    8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for <t>CDCP1</t> reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.
    Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Abcam cdcp1 antibody
    The level of <t>CDCP1</t> mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
    Cdcp1 Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cdcp1 antibody/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cdcp1 antibody - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Abcam rabbit monoclonal anti cdcp1
    The level of <t>CDCP1</t> mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
    Rabbit Monoclonal Anti Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit monoclonal anti cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit monoclonal anti cdcp1 - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Abcam antibodies rabbit monoclonal anti cdcp1 abcam cat
    The level of <t>CDCP1</t> mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.
    Antibodies Rabbit Monoclonal Anti Cdcp1 Abcam Cat, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies rabbit monoclonal anti cdcp1 abcam cat/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies rabbit monoclonal anti cdcp1 abcam cat - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Abcam antibodies against cdcp1
    The expression of <t>CDCP1</t> in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade
    Antibodies Against Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against cdcp1 - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    86
    Abcam rabbit anti cdcp1
    METTL3 modifies <t>CDCP1</t> through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.
    Rabbit Anti Cdcp1, supplied by Abcam, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cdcp1/product/Abcam
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti cdcp1 - by Bioz Stars, 2023-09
    86/100 stars
      Buy from Supplier

    Image Search Results


    Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including CDCP1. (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.

    Journal: Frontiers in Oncology

    Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

    doi: 10.3389/fonc.2023.1142755

    Figure Lengend Snippet: Extracellular vesicles (EVs) derived from ovarian cancer ascites samples. (A) Ovarian cancer (OVCA) tissue express WT-1, CA125 and ki67, scale bar 50 µm. (B) The protocol of Proximity Barcoding Assay (PBA) technology. (C) Exosomes were analyzed via nanoparticle tracking analysis. (D) Scanning Electron microscopy shows exosomes. (E) The count of EV and proteins. (F) Compared with the Con group, there were 12 upregulated, including CDCP1. (G) CDCP1 was shown higher expression in the OVCA group. ***p < 0.001.

    Article Snippet: The color was developed by diaminobenzidine at 37°C for 40 min. CDCP1 IHC was performed using an antibody against CDCP1 (Rabbit monoclonal to CDCP1-C-terminal; dilution 1:100; Abcam, ab252947; USA), as previously described.

    Techniques: Derivative Assay, Electron Microscopy, Expressing

    The CDCP1 + EVs cluster was enriched in the ascites of OVCA patients. (A) All samples were divided into twenty-eight clusters and demonstrated in the tSNE plot. (B) The Percentile of each subgroup and its characteristic protein. (C) EVs in ovarian cancer ascites and benign ascites. (D) tSNE of each sample with ovarian cancer and the control group. (E) OVCA ascites are mainly concentrated in cluster 4. (F) Major protein constituent of cluster 4.

    Journal: Frontiers in Oncology

    Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

    doi: 10.3389/fonc.2023.1142755

    Figure Lengend Snippet: The CDCP1 + EVs cluster was enriched in the ascites of OVCA patients. (A) All samples were divided into twenty-eight clusters and demonstrated in the tSNE plot. (B) The Percentile of each subgroup and its characteristic protein. (C) EVs in ovarian cancer ascites and benign ascites. (D) tSNE of each sample with ovarian cancer and the control group. (E) OVCA ascites are mainly concentrated in cluster 4. (F) Major protein constituent of cluster 4.

    Article Snippet: The color was developed by diaminobenzidine at 37°C for 40 min. CDCP1 IHC was performed using an antibody against CDCP1 (Rabbit monoclonal to CDCP1-C-terminal; dilution 1:100; Abcam, ab252947; USA), as previously described.

    Techniques:

    CDCP1 expression is associated with the prognosis of ovarian cancer patients. (A) CDCP1 expression level was positively linked with ovarian cancer in TCGA. (B) CDCP1 levels in the ascites were assessed using sandwich enzyme-linked immunosorbent assay (p < 0.05). (C) CDCP1 levels in the serum were assessed by the sandwich ELISA (p < 0.0001). (D) CDCP1 low and high expression as determined by IHC staining, scale bar 50 µm. (E) CDCP1 express level influenced survival. (F) Overall, greater ki-67 expression was associated with a shorter survival duration than low expression. (G, H) Overall and disease-free survival times of the group with high CDCP1 expression were significantly shorter than those with low CDCP1 expression. *p < 0.05, **p < 0.01, ****p < 0.0001.

    Journal: Frontiers in Oncology

    Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

    doi: 10.3389/fonc.2023.1142755

    Figure Lengend Snippet: CDCP1 expression is associated with the prognosis of ovarian cancer patients. (A) CDCP1 expression level was positively linked with ovarian cancer in TCGA. (B) CDCP1 levels in the ascites were assessed using sandwich enzyme-linked immunosorbent assay (p < 0.05). (C) CDCP1 levels in the serum were assessed by the sandwich ELISA (p < 0.0001). (D) CDCP1 low and high expression as determined by IHC staining, scale bar 50 µm. (E) CDCP1 express level influenced survival. (F) Overall, greater ki-67 expression was associated with a shorter survival duration than low expression. (G, H) Overall and disease-free survival times of the group with high CDCP1 expression were significantly shorter than those with low CDCP1 expression. *p < 0.05, **p < 0.01, ****p < 0.0001.

    Article Snippet: The color was developed by diaminobenzidine at 37°C for 40 min. CDCP1 IHC was performed using an antibody against CDCP1 (Rabbit monoclonal to CDCP1-C-terminal; dilution 1:100; Abcam, ab252947; USA), as previously described.

    Techniques: Expressing, Sandwich ELISA, Immunohistochemistry

    The  CDCP1  expression level varied between different stages.

    Journal: Frontiers in Oncology

    Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

    doi: 10.3389/fonc.2023.1142755

    Figure Lengend Snippet: The CDCP1 expression level varied between different stages.

    Article Snippet: The color was developed by diaminobenzidine at 37°C for 40 min. CDCP1 IHC was performed using an antibody against CDCP1 (Rabbit monoclonal to CDCP1-C-terminal; dilution 1:100; Abcam, ab252947; USA), as previously described.

    Techniques: Expressing

    The diagnostic value of single EV protein biomarkers. (A) Multiple protein combinations are created in the OVCA group. (B) Characteristic protein combination constituted of CDCP1 in the OVCA group. (C) The receiver operating characteristic (ROC) curve for CDCP1. (D) The ROC curve for the combination of proteins CDCP1 and ITGA6.

    Journal: Frontiers in Oncology

    Article Title: Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer

    doi: 10.3389/fonc.2023.1142755

    Figure Lengend Snippet: The diagnostic value of single EV protein biomarkers. (A) Multiple protein combinations are created in the OVCA group. (B) Characteristic protein combination constituted of CDCP1 in the OVCA group. (C) The receiver operating characteristic (ROC) curve for CDCP1. (D) The ROC curve for the combination of proteins CDCP1 and ITGA6.

    Article Snippet: The color was developed by diaminobenzidine at 37°C for 40 min. CDCP1 IHC was performed using an antibody against CDCP1 (Rabbit monoclonal to CDCP1-C-terminal; dilution 1:100; Abcam, ab252947; USA), as previously described.

    Techniques: Diagnostic Assay

    8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for CDCP1 reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.

    Journal: Molecular Oncology

    Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    doi: 10.1002/1878-0261.13429

    Figure Lengend Snippet: 8‐Isopentenylnaringenin is identified from a compound library by screening its capacity for CDCP1 reduction and has antimigration effects on lung cancer cells. (A) Schematic design of screening CDCP1 inhibitors. (B) The top compound, 8PN, was identified by our cell‐based screen. The structure was drawn using chembiodraw ultra 14.0 (CambridgeSoft corporation, Cambridge, MA, USA). (C) Immunoblotting analysis of CDCP1 in TC1 and Bm7 lung cancer cells after 8PN treatment for 24 h. EF1α was the loading control. Similar results were detected at least three times. (D) Migration distance of lung cancer cells was measured by time‐lapse migration assays in TC1 cells with 20 μ m 8PN and in Bm7 cells with 25 μ m 8PN. Each colored dot and line represents one trace of an individual cell. Black and red lines represent movement in opposite directions. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05.

    Article Snippet: After 1 h of blocking, primary antibodies were used against the following targets: CDCP1 (ab1377; Abcam, Cambridge, MA, USA), retinoblastoma protein (RB; #2947; Cell Signaling Technology, Danvers, MA, USA), phosphorylated RB (#8516; Cell Signaling Technology), cyclin E1 (ab33911; Abcam), cyclin E2 (ab40890; Abcam), EGFR (sc‐373746; Santa Cruz, Dallas, Texas, USA), phosphorylated EGFR (p‐EGFR; ab1377 and ab32894; Abcam), phosphorylated ERK (p‐ERK; #9101; Cell Signaling Technology), ERK (#9102; Cell Signaling Technology), and caspase 3 (#9661s; Cell Signaling Technology, or ab1899; Millipore, Billerica, MA, USA).

    Techniques: Library Screening, Western Blot, Migration, Standard Deviation

    8‐Isopentenylnaringenin dose‐dependently suppresses lung cancer colony formation and sphere formation ability. (A) Colony formation was analyzed after 7 days of 8PN treatment in TC1, Bm7, and H1650 cells. Experiments were performed in three replicate wells. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (B) The number of spheres was measured 12 days post‐treatment in TC1 cells with 20 μ m 8PN, Bm7 cells with 25 μ m 8PN, and H1650 cells with 12.5 μ m 8PN ( n = 3). Scale bar, 50 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (C) Immunoblotting analysis of CDCP1, CD44, and CD133 in Bm7 sphere cells with 25 μ m 8PN and H1650 sphere cells with 50 μ m 8PN for 9 days. Actin was the loading control. Experiments were repeated in three times.

    Journal: Molecular Oncology

    Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    doi: 10.1002/1878-0261.13429

    Figure Lengend Snippet: 8‐Isopentenylnaringenin dose‐dependently suppresses lung cancer colony formation and sphere formation ability. (A) Colony formation was analyzed after 7 days of 8PN treatment in TC1, Bm7, and H1650 cells. Experiments were performed in three replicate wells. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (B) The number of spheres was measured 12 days post‐treatment in TC1 cells with 20 μ m 8PN, Bm7 cells with 25 μ m 8PN, and H1650 cells with 12.5 μ m 8PN ( n = 3). Scale bar, 50 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. * P < 0.05. (C) Immunoblotting analysis of CDCP1, CD44, and CD133 in Bm7 sphere cells with 25 μ m 8PN and H1650 sphere cells with 50 μ m 8PN for 9 days. Actin was the loading control. Experiments were repeated in three times.

    Article Snippet: After 1 h of blocking, primary antibodies were used against the following targets: CDCP1 (ab1377; Abcam, Cambridge, MA, USA), retinoblastoma protein (RB; #2947; Cell Signaling Technology, Danvers, MA, USA), phosphorylated RB (#8516; Cell Signaling Technology), cyclin E1 (ab33911; Abcam), cyclin E2 (ab40890; Abcam), EGFR (sc‐373746; Santa Cruz, Dallas, Texas, USA), phosphorylated EGFR (p‐EGFR; ab1377 and ab32894; Abcam), phosphorylated ERK (p‐ERK; #9101; Cell Signaling Technology), ERK (#9102; Cell Signaling Technology), and caspase 3 (#9661s; Cell Signaling Technology, or ab1899; Millipore, Billerica, MA, USA).

    Techniques: Standard Deviation, Western Blot

    8‐Isopentenylnaringenin induces cell cycle arrest in G0/G1 phase and senescence. (A) Immunoblotting analysis of cell cycle proteins in Bm7 cells with 25 μ m 8PN and H1650 cells with 50 μ m 8PN for 48 h. Actin was the loading control. (B) β‐Galactosidase staining in lung cancer cells after treatment with the indicated dose of 8PN for 6 days. The number of senescent cells was quantified using the imagej software. Representative images shown in the lower panel. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. (C) β‐Galactosidase staining in CDCP1‐depleted lung cancer cells after treatment with the indicated dose of 8PN for 6 days. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05, ** P < 0.01.

    Journal: Molecular Oncology

    Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    doi: 10.1002/1878-0261.13429

    Figure Lengend Snippet: 8‐Isopentenylnaringenin induces cell cycle arrest in G0/G1 phase and senescence. (A) Immunoblotting analysis of cell cycle proteins in Bm7 cells with 25 μ m 8PN and H1650 cells with 50 μ m 8PN for 48 h. Actin was the loading control. (B) β‐Galactosidase staining in lung cancer cells after treatment with the indicated dose of 8PN for 6 days. The number of senescent cells was quantified using the imagej software. Representative images shown in the lower panel. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. (C) β‐Galactosidase staining in CDCP1‐depleted lung cancer cells after treatment with the indicated dose of 8PN for 6 days. Scale bar, 40 μm. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. Experiments were performed in three replicates. * P < 0.05, ** P < 0.01.

    Article Snippet: After 1 h of blocking, primary antibodies were used against the following targets: CDCP1 (ab1377; Abcam, Cambridge, MA, USA), retinoblastoma protein (RB; #2947; Cell Signaling Technology, Danvers, MA, USA), phosphorylated RB (#8516; Cell Signaling Technology), cyclin E1 (ab33911; Abcam), cyclin E2 (ab40890; Abcam), EGFR (sc‐373746; Santa Cruz, Dallas, Texas, USA), phosphorylated EGFR (p‐EGFR; ab1377 and ab32894; Abcam), phosphorylated ERK (p‐ERK; #9101; Cell Signaling Technology), ERK (#9102; Cell Signaling Technology), and caspase 3 (#9661s; Cell Signaling Technology, or ab1899; Millipore, Billerica, MA, USA).

    Techniques: Western Blot, Staining, Software, Standard Deviation

    Loss of CDCP1 in lung cancer cells significantly increases lung cancer cell death. (A) Levels of CDCP1, caspase 3, phospho‐EGFR, and phospho‐ERK were detected in H1650 cells treated with 50 μ m 8PN and/or 2.5 μ m afatinib (left) and H1975 cells treated with 40 μ m 8PN and/or 1 μ m AZD (right). Experiments were repeated in three times. (B) Levels of indicated proteins were detected in control (shVOID) and CDCP1 knockdown (shCDCP1) H1650 (left) and H1975 (right) cells treated with 1 μ m afatinib or 10 μ m AZD. Experiments were repeated in three times. (C) H1650 ( n = 6) and H1975 cells ( n = 4) were treated with EGFR TKI for 3 and 9 days, respectively. The cell viability was assessed by colony formation assays. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. ** P < 0.01.

    Journal: Molecular Oncology

    Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    doi: 10.1002/1878-0261.13429

    Figure Lengend Snippet: Loss of CDCP1 in lung cancer cells significantly increases lung cancer cell death. (A) Levels of CDCP1, caspase 3, phospho‐EGFR, and phospho‐ERK were detected in H1650 cells treated with 50 μ m 8PN and/or 2.5 μ m afatinib (left) and H1975 cells treated with 40 μ m 8PN and/or 1 μ m AZD (right). Experiments were repeated in three times. (B) Levels of indicated proteins were detected in control (shVOID) and CDCP1 knockdown (shCDCP1) H1650 (left) and H1975 (right) cells treated with 1 μ m afatinib or 10 μ m AZD. Experiments were repeated in three times. (C) H1650 ( n = 6) and H1975 cells ( n = 4) were treated with EGFR TKI for 3 and 9 days, respectively. The cell viability was assessed by colony formation assays. Statistical analyses were determined by the Student's t ‐test. Data are shown as mean ± standard deviation. ** P < 0.01.

    Article Snippet: After 1 h of blocking, primary antibodies were used against the following targets: CDCP1 (ab1377; Abcam, Cambridge, MA, USA), retinoblastoma protein (RB; #2947; Cell Signaling Technology, Danvers, MA, USA), phosphorylated RB (#8516; Cell Signaling Technology), cyclin E1 (ab33911; Abcam), cyclin E2 (ab40890; Abcam), EGFR (sc‐373746; Santa Cruz, Dallas, Texas, USA), phosphorylated EGFR (p‐EGFR; ab1377 and ab32894; Abcam), phosphorylated ERK (p‐ERK; #9101; Cell Signaling Technology), ERK (#9102; Cell Signaling Technology), and caspase 3 (#9661s; Cell Signaling Technology, or ab1899; Millipore, Billerica, MA, USA).

    Techniques: Standard Deviation

    Schematic diagram showing that 8PN reduces CDCP1 protein levels and increases IL6 and IL8 expression in lung tumors to attract neutrophil infiltration. The combination of 8PN and EGFR TKI produces synergistic effects in lung cancer treatment.

    Journal: Molecular Oncology

    Article Title: Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

    doi: 10.1002/1878-0261.13429

    Figure Lengend Snippet: Schematic diagram showing that 8PN reduces CDCP1 protein levels and increases IL6 and IL8 expression in lung tumors to attract neutrophil infiltration. The combination of 8PN and EGFR TKI produces synergistic effects in lung cancer treatment.

    Article Snippet: After 1 h of blocking, primary antibodies were used against the following targets: CDCP1 (ab1377; Abcam, Cambridge, MA, USA), retinoblastoma protein (RB; #2947; Cell Signaling Technology, Danvers, MA, USA), phosphorylated RB (#8516; Cell Signaling Technology), cyclin E1 (ab33911; Abcam), cyclin E2 (ab40890; Abcam), EGFR (sc‐373746; Santa Cruz, Dallas, Texas, USA), phosphorylated EGFR (p‐EGFR; ab1377 and ab32894; Abcam), phosphorylated ERK (p‐ERK; #9101; Cell Signaling Technology), ERK (#9102; Cell Signaling Technology), and caspase 3 (#9661s; Cell Signaling Technology, or ab1899; Millipore, Billerica, MA, USA).

    Techniques: Expressing

    The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Expressing

    CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Cell Culture, Two Tailed Test

    The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Expressing, Western Blot, Two Tailed Test

    The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Two Tailed Test

    Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Imaging, Microscopy, Staining

    The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Two Tailed Test

    The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Two Tailed Test

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet:

    Article Snippet: CDCP1 antibody (Abcam, ab245839) was diluted 100 times with 3% BSA, and the samples were incubated with the antibody at 4°C overnight.

    Techniques: Recombinant, Lysis, Blocking Assay, Western Blot, Software

    The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The level of CDCP1 mRNA in pan-cancer and its prognostic significance in NSCLC (A) The mRNA level of CDCP1 in different types of human cancer (Gepia2). In the name of cancer type, red represents a significantly higher expression level and green represents a significantly lower expression level. T for tumor tissue and N for normal tissue. (B–D) Kaplan-Meier survival curve analysis of the prognostic value of high and low expression of CDCP1 in patients with LUAD and LUSC (Kaplan-Meier plotter). High CDCP1 expression was associated with worse OS (B) and RFS (D) in LUAD. High CDCP1 expression was associated with worse OS in LUSC (C). Survival curves of RFS in LUSC (E). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; RFS, recurrence-free survival.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Expressing

    CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: CDCP1 proteins formed different numbers and sizes of clusters on cultured lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on HBE cell (A) and SK-MES-1 cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: a and b, 5 μm; c and d, 2 μm). (E) The number of CDCP1 localizations per μm 2 on HBE and SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Cell Culture, Two Tailed Test

    The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The changes of CDCP1 clusters after treatment of EGF and protein expression of CDCP1 by Western blot (A–D) Reconstructed dSTORM images of CDCP1 on control (A) and EGF-treated (C) SK-MES-1 cell membranes, and the corresponding magnified images (B and D). (Scale bars: A and C, 5 μm; B and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on control and EGF-treated SK-MES-1 cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. (I) Western blot of CDCP1 in SK-MES-1 cells, HBE cells, and EGF-treated SK-MES-1 cells. (J) Statistical analysis of CDCP1 expression levels. Data were obtained from three independent experiments (mean ± SD) and statistical significance was processed by two-tailed paired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Expressing, Western Blot, Two Tailed Test

    The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The distribution of CDCP1 on primary non-small lung cancer cells and normal cells (A and B) Reconstructed dSTORM images of CDCP1 on primary normal cell (A) and primary non-small lung cancer cell membrane (B). (C and D) The corresponding magnified images of (A and B). (Scale bars: A and B, 5 μm; C and D, 2 μm). (E) The number of CDCP1 localizations per μm 2 on primary non-small lung cancer cell and normal cell membranes. (F) The number of CDCP1 clusters per μm 2 . (G) The percentage of CDCP1 cluster area in each cell. (H) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Two Tailed Test

    Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: Imaging of cancer tissue and matched normal tissue sections under the common fluorescent microscope (100×) (A and E) Images of immunofluorescent staining of CDCP1 protein in fluorescent-field illumination. (B and F) Nuclear staining images. (C and G) The merged images of CDCP1 protein and nucleus. (D and H) The corresponding magnified images of (C and G). (Scale bars: A–C and E–G, 10 μm; D and H, 2 μm).

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Imaging, Microscopy, Staining

    The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The super-resolution images of cancer tissue and matched normal tissue sections (100×) (A and G) Images of cancer tissue and normal tissue sections in bright-field illumination. (B and H) TIRF images of CDCP1 on normal tissue section (B) and cancer tissue section (H). (C and I) Reconstructed dSTORM images of CDCP1 on cancer tissue and matched normal tissue sections, and (D and J) the corresponding magnified images. (E and K) The corresponding cluster distribution images of (D and J) analyzed by SR-Tesseler (red areas represent clusters). (F and L) The progressively zoomed regions of (E and K). (Scale bars: A–C and G–I, 5 μm; D, E and J, K, 2 μm; F and L, 500 nm). (M) The number of CDCP1 localizations per μm 2 on cancer tissue and matched normal tissue sections. (N) The number of CDCP1 clusters per μm 2 . (O) The percentage of CDCP1 cluster area in each cell. (P) The percentage of CDCP1 clusters containing different number of localizations in cancer tissues. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗∗∗∗p < 0.0001.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Two Tailed Test

    The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet: The changes of CDCP1 clusters after treatment of PP2 (A, B, E, and F) Reconstructed dSTORM images of CDCP1 on control (A) and PP2-treated (E) SK-MES-1 cell membranes, and the corresponding magnified images (B and F). (C, D, G, and H) The corresponding cluster distribution images of (A, B, E, and F) analyzed by SR-Tesseler (red areas represent clusters). (Scale bars: 5 μm for A, E, C, G; 2 μm for B, F, D, H.). (I) The number of CDCP1 localizations per μm 2 on control and PP2-treated SK-MES-1 cell membranes. (J) The number of CDCP1 clusters per μm 2 . (K) The percentage of CDCP1 cluster area in each cell. (L) The percentage of CDCP1 clusters containing different number of localizations. All data were obtained from 10 cell samples in 3 independent experiments (mean ± SD) and statistical significance was processed by two-tailed unpaired t-test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, and ns means not significant.

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Two Tailed Test

    Journal: iScience

    Article Title: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging

    doi: 10.1016/j.isci.2023.106103

    Figure Lengend Snippet:

    Article Snippet: Rabbit monoclonal anti-CDCP1 , Abcam , Cat#ab245839.

    Techniques: Recombinant, Lysis, Blocking Assay, Western Blot, Software

    The expression of CDCP1 in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: The expression of CDCP1 in glioma. A The expression of CDCP1 in GBM and other tumors ( BLCA bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon adenocarcinoma, GBM glioblastoma, KICH kidney chromophobe, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, READ rectum adenocarcinoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumors, UCEC uterine corpus endometrial carcinoma). In the TCGA data B and GSE50161 ( C ), the expression of CDCP1 in GBM tissue was significantly higher than that in normal brain tissue. In the TCGA data D and CGGA data ( E ), CDCP1 mRNA expression increased with increasing glioma grade

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing

    The expression of CDCP1 was verified in glioma specimens from a southern hospital. Immunohistochemistry A verified CDCP1 expression in 35 samples of WHO grade II, 42 samples of WHO grade III and 55 samples of WHO grade IV glioma, and analysis of the immune scores B demonstrated that CDCP1 expression increased significantly with increasing WHO grade. Western blot C confirmed that CDCP1 expression was significantly increased in GBM (in the HCT116 human colorectal cancer cell line with high CDCP1 expression)

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: The expression of CDCP1 was verified in glioma specimens from a southern hospital. Immunohistochemistry A verified CDCP1 expression in 35 samples of WHO grade II, 42 samples of WHO grade III and 55 samples of WHO grade IV glioma, and analysis of the immune scores B demonstrated that CDCP1 expression increased significantly with increasing WHO grade. Western blot C confirmed that CDCP1 expression was significantly increased in GBM (in the HCT116 human colorectal cancer cell line with high CDCP1 expression)

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing, Immunohistochemistry, Western Blot

    Kaplan–Meier survival curve and multivariate Cox regression analyses of the CDCP1 risk score in the TCGA A – C (n = 667) and CGGA (B-D) datasets(n = 966)

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Kaplan–Meier survival curve and multivariate Cox regression analyses of the CDCP1 risk score in the TCGA A – C (n = 667) and CGGA (B-D) datasets(n = 966)

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques:

    Functional analysis of CDCP1 in GBM. GSEA (A-B) of GO functions and KEGG pathways of CDCP1 in the CGGA data. Identification of differentially expressed genes related to changes in CDCP1 expression ( C – D ). GO functional analysis E and KEGG pathway analysis F of 2408 upregulated genes

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Functional analysis of CDCP1 in GBM. GSEA (A-B) of GO functions and KEGG pathways of CDCP1 in the CGGA data. Identification of differentially expressed genes related to changes in CDCP1 expression ( C – D ). GO functional analysis E and KEGG pathway analysis F of 2408 upregulated genes

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Functional Assay, Expressing

    Verification of CDCP1 function in vitro. Transwell assays A and cell migration assays B showed that CDCP1 overexpression promoted the migration ability of glioma cells in vitro ( Wilcoxon rank-sum test)(the magnification is 200 times). Western blotting C was performed to detect the expression of N-cadherin, vimentin and Slug in the LV-CDCP1 and LV-Con groups

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Verification of CDCP1 function in vitro. Transwell assays A and cell migration assays B showed that CDCP1 overexpression promoted the migration ability of glioma cells in vitro ( Wilcoxon rank-sum test)(the magnification is 200 times). Western blotting C was performed to detect the expression of N-cadherin, vimentin and Slug in the LV-CDCP1 and LV-Con groups

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: In Vitro, Migration, Over Expression, Western Blot, Expressing

    Analysis of the molecular mechanism of CDCP1 in GBM. Identification of key genes in the PPI network (A-B). High expression of CDCP1 was associated with MES-GBM. The correlation between CDCP1 expression and the mesenchymal C – E or proneural C – H signature was assessed using the CGGA database. Immunohistochemistry verification of the correlation between CDCP1 and CD44 expression ( I ). Western blot verification of the correlation between CDCP1 and CD44 expression J (Wilcoxon rank-sum test)

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Analysis of the molecular mechanism of CDCP1 in GBM. Identification of key genes in the PPI network (A-B). High expression of CDCP1 was associated with MES-GBM. The correlation between CDCP1 expression and the mesenchymal C – E or proneural C – H signature was assessed using the CGGA database. Immunohistochemistry verification of the correlation between CDCP1 and CD44 expression ( I ). Western blot verification of the correlation between CDCP1 and CD44 expression J (Wilcoxon rank-sum test)

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing, Immunohistochemistry, Western Blot

    Correlation between the protein expression of  CDCP1  and CD44 in GBM tissue samples

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Correlation between the protein expression of CDCP1 and CD44 in GBM tissue samples

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing

    Correlation between the protein expression of  CDCP1  and ITGAM in GBM tissue samples

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Correlation between the protein expression of CDCP1 and ITGAM in GBM tissue samples

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing

    Establishment and verification of the prognostic risk model. Construction of a PPI network with key genes and CDCP1 ( A ). Establishment of the prognostic risk model comprising CDCP1, CD44 and ITGAM expression ( B ). Survival curves for glioma C and GBM D patients based on the prognostic risk model. Nomogram based on the risk model and clinicopathological factors. E: Glioma patient data. F: GBM patient data

    Journal: Cancer Cell International

    Article Title: Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

    doi: 10.1186/s12935-021-02373-1

    Figure Lengend Snippet: Establishment and verification of the prognostic risk model. Construction of a PPI network with key genes and CDCP1 ( A ). Establishment of the prognostic risk model comprising CDCP1, CD44 and ITGAM expression ( B ). Survival curves for glioma C and GBM D patients based on the prognostic risk model. Nomogram based on the risk model and clinicopathological factors. E: Glioma patient data. F: GBM patient data

    Article Snippet: After endogenous peroxidase was blocked with 3% hydrogen peroxide and nonspecific antigens were blocked with 5% bovine serum albumin, incubation was performed with antibodies against CDCP1 (Abcam, catalog #ab1377, human, 1:100), CD44 (Abcam, catalog #ab189524, human, 1:100), and ITGAM (Cell Signaling Technology, catalog #23743, human, 1:100).

    Techniques: Expressing

    METTL3 modifies CDCP1 through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.

    Journal: Aging (Albany NY)

    Article Title: Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer

    doi: 10.18632/aging.103822

    Figure Lengend Snippet: METTL3 modifies CDCP1 through m6A to elevate the CDCP1 expression, driving the proliferation and invasion of GC cells. ( A ) The co-expression map of METTL3 and CDCP1 obtained by MEM analysis ( p = 5.32E-03; https://biit.cs.ut.ee/mem/index.cgi ). ( B ) Correlation between METTL3 and CDCP1 expression obtained by GEPIA analysis ( http://gepia2.cancer-pku.cn ) of GC data (R = 0.17, p = 4.2E-04), absolute expression of mRNAs from GEPIA is presented. ( C ) Absolute CDCP1 expression in GC obtained by UALCAN. The blue box on the left represents the expression of normal samples, and the red box on the right represents the expression of GC samples. ( D ) Western blot assay and RT-qPCR to measure METTL3 and CDCP1 expression in MGC-803 and HGC-27 cells, with β-actin as internal control. ( E ) Me-RIP assay to examine m6A level of CDCP1 mRNA and enrichment after METTL3 knockdown. ( F ) Quantitative analysis for luciferase activity after METTL3 knockdown. ( G ) CCK-8 assay for cell viability in response to METTL3 knockdown and CDCP1 overexpression. ( H ) Colony formation assay to assess the number of colonies in response to METTL3 knockdown and CDCP1 overexpression. ( I ) Transwell assay to assess the number of invaded cells in response to METTL3 knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Unpaired t test was employed for data comparison between two groups. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. Cell experiments were repeated 3 times independently.

    Article Snippet: After blocking the PVDF membrane for 1 h, it was incubated at 4° C overnight with diluted primary antibodies: rabbit anti-EED (1 : 1000, PA5-34430, Invitrogen), rabbit anti-METTL3 (1 : 1000, ab195352, Abcam, Cambridge, UK), rabbit anti-CDCP1 (1 : 1000, ab1377, Abcam), and murine anti-β-Actin (1 : 5000, ab8227, Abcam).

    Techniques: Expressing, Western Blot, Quantitative RT-PCR, Luciferase, Activity Assay, CCK-8 Assay, Over Expression, Colony Assay, Transwell Assay, Standard Deviation

    EED accelerates the progression of GC in vivo through the miR-338-5p/METTL3/CDCP1 axis. ( A ) RT-qPCR to examine the expression of EED/miR-338-5p/METTL3/CDCP1 in tumors of nude mice, with β-actin and U6 as internal control, respectively. ( B ) Immunohistochemistry to detect METTL3 and CDCP1 expression in mouse tumors. ( C ) Tumor volume and tumor photos in response to EED knockdown and CDCP1 overexpression. ( D ) Quantitative analysis for tumor weight in response to EED knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. n = 6.

    Journal: Aging (Albany NY)

    Article Title: Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer

    doi: 10.18632/aging.103822

    Figure Lengend Snippet: EED accelerates the progression of GC in vivo through the miR-338-5p/METTL3/CDCP1 axis. ( A ) RT-qPCR to examine the expression of EED/miR-338-5p/METTL3/CDCP1 in tumors of nude mice, with β-actin and U6 as internal control, respectively. ( B ) Immunohistochemistry to detect METTL3 and CDCP1 expression in mouse tumors. ( C ) Tumor volume and tumor photos in response to EED knockdown and CDCP1 overexpression. ( D ) Quantitative analysis for tumor weight in response to EED knockdown and CDCP1 overexpression. Measurement data are expressed as mean ± standard deviation. * p < 0.05. Data comparison among multiple groups was performed using one-way ANOVA with Tukey's post hoc test. Data comparison between groups at different time points was performed using two-way ANOVA or repeated-measures ANOVA with Bonferroni post hoc test. n = 6.

    Article Snippet: After blocking the PVDF membrane for 1 h, it was incubated at 4° C overnight with diluted primary antibodies: rabbit anti-EED (1 : 1000, PA5-34430, Invitrogen), rabbit anti-METTL3 (1 : 1000, ab195352, Abcam, Cambridge, UK), rabbit anti-CDCP1 (1 : 1000, ab1377, Abcam), and murine anti-β-Actin (1 : 5000, ab8227, Abcam).

    Techniques: In Vivo, Quantitative RT-PCR, Expressing, Immunohistochemistry, Over Expression, Standard Deviation

    The mechanism graph of the regulatory network and function of EED-mediated miR-338-5p methylation. EED methylates miR-338-5p to repress its expression, and upregulates expression of miR-338-5p’s target METTL3. METTL3 modifies CDCP1 mRNA through m6A to promote CDCP1 translation, leading to GC progression.

    Journal: Aging (Albany NY)

    Article Title: Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer

    doi: 10.18632/aging.103822

    Figure Lengend Snippet: The mechanism graph of the regulatory network and function of EED-mediated miR-338-5p methylation. EED methylates miR-338-5p to repress its expression, and upregulates expression of miR-338-5p’s target METTL3. METTL3 modifies CDCP1 mRNA through m6A to promote CDCP1 translation, leading to GC progression.

    Article Snippet: After blocking the PVDF membrane for 1 h, it was incubated at 4° C overnight with diluted primary antibodies: rabbit anti-EED (1 : 1000, PA5-34430, Invitrogen), rabbit anti-METTL3 (1 : 1000, ab195352, Abcam, Cambridge, UK), rabbit anti-CDCP1 (1 : 1000, ab1377, Abcam), and murine anti-β-Actin (1 : 5000, ab8227, Abcam).

    Techniques: Methylation, Expressing

    Primer sequences for RT-qPCR.

    Journal: Aging (Albany NY)

    Article Title: Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer

    doi: 10.18632/aging.103822

    Figure Lengend Snippet: Primer sequences for RT-qPCR.

    Article Snippet: After blocking the PVDF membrane for 1 h, it was incubated at 4° C overnight with diluted primary antibodies: rabbit anti-EED (1 : 1000, PA5-34430, Invitrogen), rabbit anti-METTL3 (1 : 1000, ab195352, Abcam, Cambridge, UK), rabbit anti-CDCP1 (1 : 1000, ab1377, Abcam), and murine anti-β-Actin (1 : 5000, ab8227, Abcam).

    Techniques: Sequencing